Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 74 peer-reviewed journal articles Updated
Ophthalmology

Intermediate Uveitis: A Patient Guide

At a Glance

Intermediate uveitis is a quiet, long-lasting inflammation inside the eye that may cause floaters or blurred vision without much pain or redness. Doctors look for infections and related conditions, then use tailored treatment and regular scans to prevent swelling and permanent vision loss.

Disclaimer: This guide provides general education about intermediate uveitis, which has multiple causes and severities. It is not medical advice. Never start, stop, or rapidly taper corticosteroids or immunosuppressive medicines without guidance from your prescribing team.

Intermediate uveitis is a chronic form of eye inflammation that primarily affects the middle of the eye, specifically the clear gel-like fluid known as the vitreous, the pars plana (a small area near the front of the eye), and the blood vessels in the peripheral retina [1][2]. Unlike other types of uveitis that cause immediate pain or redness, this condition is often “quiet,” presenting instead with subtle signs like floating spots, hazy vision, or a gradual blurring of sight. Because it can develop slowly and persist over many years, the journey often begins with a rigorous diagnostic process to determine if the inflammation is “idiopathic” (occurring on its own, such as in pars planitis) or a signal of a broader systemic condition like sarcoidosis or multiple sclerosis [3][4][5].

Identifying the root cause is essential because it dictates the treatment path. Doctors must evaluate for infectious “mimics” like syphilis or Lyme disease, as the medications used to suppress the immune system could otherwise be harmful if an infection is present and untreated [6][7]. Once an infection is appropriately managed or ruled out, an individualized treatment strategy is typically used. This often begins with corticosteroids to quiet the eye and may move toward long-term “steroid-sparing” therapies (immunomodulators) or biologic medications if the inflammation persists or if steroid side effects become a concern [8][9]. The ultimate goal of these therapies is not just to clear the “haze” of the inflammation, but to prevent structural damage to the eye that could lead to permanent vision loss [10].

The most significant threat to vision in intermediate uveitis is Cystoid Macular Edema (CME), a swelling in the central part of the retina responsible for detail [11]. Because complications like CME, cataracts, or glaucoma can develop even when you feel your vision is stable, consistent monitoring with specialized tools like Optical Coherence Tomography (OCT) is the most important part of long-term care [12][13]. This surveillance allows your care team—which is led by an ophthalmologist but may include rheumatologists or neurologists if indicated—to detect microscopic changes and adjust your treatment before your sight is impacted [14][15].

While a chronic diagnosis can feel daunting, modern medicine provides multiple effective pathways to manage the inflammation and protect your eyes. For many patients, active participation in a long-term care plan leads to a favorable visual outcome and the ability to maintain an active lifestyle, although this depends heavily on the underlying cause, whether one or both eyes are affected, and how the eye responds to treatment [16][17]. By staying informed, adhering to your monitoring schedule, and working closely with your specialist team, you can take control of your eye health and confidently navigate the road ahead.

In this guide

6 chapters

01

Orientation & Understanding Your Diagnosis

Learn what intermediate uveitis means, how doctors find its cause, possible complications such as retinal swelling, and how eye exams help protect your vision.

02

Symptoms & Warning Signs

Learn to recognize intermediate uveitis symptoms, including floaters, blurred vision, flares, and warning signs such as flashes, shadows, or sudden vision loss.

03

Diagnostics & Ruling Out Mimics

Learn how intermediate uveitis is diagnosed, including infection testing, chest imaging, OCT, and fluorescein angiography to rule out mimics and monitor vision.

04

Standard of Care Treatment Strategy

Learn how intermediate uveitis is treated, from observation and steroids to immunomodulators, biologics, and vitrectomy, including key safety tests and risks.

05

Complications & Structural Monitoring

Learn how intermediate uveitis can cause macular swelling, cataracts, glaucoma, and retinal changes, plus how OCT scans and eye-pressure checks protect vision.

06

Long-Term Monitoring & Building Your Care Team

Learn how long-term monitoring, OCT scans, eye exams, care teams, medication safety, and emotional support help protect vision with intermediate uveitis.

Common questions in this guide

What is intermediate uveitis, and how might I notice it?
Intermediate uveitis is long-lasting inflammation mainly affecting the clear gel inside the eye and nearby tissues. It may cause floaters, hazy vision, or gradually blurred sight, often without much pain or visible redness.
What can cause intermediate uveitis?
Sometimes no specific cause is found; this is called idiopathic intermediate uveitis and may be described as pars planitis. Doctors also look for conditions such as sarcoidosis or multiple sclerosis and for infections that can mimic the condition, including syphilis or Lyme disease.
Why must infections be checked before immune-suppressing medicines?
Infections such as syphilis or Lyme disease can resemble intermediate uveitis. Immune-suppressing medicines may worsen an untreated infection, so doctors evaluate for infectious causes before using treatment that lowers immune activity.
How is intermediate uveitis monitored if my vision feels stable?
Your ophthalmologist may use eye examinations, pressure checks, and optical coherence tomography (OCT) scans to track inflammation and early complications. Regular monitoring can identify swelling in the central retina, cataracts, or glaucoma before you notice a major change in vision.
What treatments might be used for intermediate uveitis?
Treatment often begins with corticosteroids to reduce inflammation after important infections have been evaluated or treated. If inflammation persists or steroid side effects become a concern, your care team may consider longer-term steroid-sparing immune medicines or biologic medications.
Can intermediate uveitis lead to permanent vision loss?
It can, especially when complications such as cystoid macular edema cause damage to the central retina or inflammation remains uncontrolled. Regular follow-up and timely treatment aim to protect vision, but outlook varies with the cause, whether one or both eyes are affected, and response to treatment.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Intermediate uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do we determine if my (or my child’s) case is idiopathic pars planitis or related to a systemic condition?
  2. 2.What is the current level of inflammation in the vitreous, and how will we monitor it over time?
  3. 3.What are the early signs of cystoid macular edema (CME) that I should be watching for at home?
  4. 4.Which specialists—such as a rheumatologist or neurologist—might be appropriate for my care team right now?
  5. 5.What is the long-term plan if my inflammation becomes 'steroid-dependent'?

References

References (17)
  1. 1

    Intermediate Uveitis: A Review.

    Teo AYT, Betzler BK, Hua KLQ, et al.

    Ocular immunology and inflammation 2023; (31(5)):1041-1060 doi:10.1080/09273948.2022.2070503.

    PMID: 35759636
  2. 2

    Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis.

    Ozdal PC, Berker N, Tugal-Tutkun I

    Journal of ophthalmic & vision research 2015; (10(4)):469-80 doi:10.4103/2008-322X.176897.

    PMID: 27051493
  3. 3

    Classification Criteria For Pars Planitis.

    American journal of ophthalmology 2021; (228()):268-274 doi:10.1016/j.ajo.2021.03.045.

    PMID: 33845006
  4. 4

    Classification Criteria for Sarcoidosis-Associated Uveitis.

    American journal of ophthalmology 2021; (228()):220-230 doi:10.1016/j.ajo.2021.03.047.

    PMID: 33845001
  5. 5

    Insights into multiple sclerosis-associated uveitis: a scoping review.

    Casselman P, Cassiman C, Casteels I, Schauwvlieghe PP

    Acta ophthalmologica 2021; (99(6)):592-603 doi:10.1111/aos.14697.

    PMID: 33326162
  6. 6

    Classification Criteria for Syphilitic Uveitis.

    American journal of ophthalmology 2021; (228()):182-191 doi:10.1016/j.ajo.2021.03.039.

    PMID: 33845020
  7. 7

    Intraocular Metastatic Lung Adenocarcinoma Masquerading as an Intermediate Uveitis.

    Nguyen RD, Livnat I, Krishnan V, et al.

    Ocular immunology and inflammation 2026; (34(2)):242-245 doi:10.1080/09273948.2024.2447846.

    PMID: 39804108
  8. 8

    Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial.

    , Jabs DA, Sugar EA, et al.

    Ophthalmology 2026; (133(3)):310-325 doi:10.1016/j.ophtha.2025.10.004.

    PMID: 41077357
  9. 9

    Pediatric Uveitis.

    Chan NS, Choi J, Cheung CMG

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; (7(3)):192-199 doi:10.22608/APO.2018116.

    PMID: 29682916
  10. 10

    Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

    , Kempen JH, Altaweel MM, et al.

    Ophthalmology 2015; (122(10)):1967-75.

    PMID: 26298715
  11. 11

    Correlation between Morphological Characteristics of Macular Edema and Visual Acuity in Young Patients with Idiopathic Intermediate Uveitis.

    Iannetti L, Scarinci F, Alisi L, et al.

    Medicina (Kaunas, Lithuania) 2023; (59(3)) doi:10.3390/medicina59030529.

    PMID: 36984530
  12. 12

    Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant.

    Rossetto JD, Nascimento H, Fernandes DD, et al.

    Arquivos brasileiros de oftalmologia 2015; (78(3)):190-3.

    PMID: 26222112
  13. 13

    Risk of Cataract in Intermediate Uveitis.

    Minkus CL, Pistilli M, Dreger KA, et al.

    American journal of ophthalmology 2021; (229()):200-209 doi:10.1016/j.ajo.2021.02.032.

    PMID: 33713679
  14. 14

    Clinical Course and Treatment Paradigms for JIA-related Uveitis and Pars Planitis Uveitis Using Precise Ocular Investigational Methods.

    Papasavvas I, Gehrig B, Herbort CP

    Klinische Monatsblatter fur Augenheilkunde 2021; (238(4)):458-468 doi:10.1055/a-1354-6452.

    PMID: 33607692
  15. 15

    An Overview of Pediatric Uveitis.

    Tuğal-Tutkun İ

    Turkish archives of pediatrics 2023; (58(4)):363-370 doi:10.5152/TurkArchPediatr.2023.23086.

    PMID: 37357450
  16. 16

    Predictors of Long-Term Visual Outcome in Intermediate Uveitis.

    Niederer RL, Sharief L, Bar A, et al.

    Ophthalmology 2017; (124(3)):393-398 doi:10.1016/j.ophtha.2016.11.013.

    PMID: 28017424
  17. 17

    Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis.

    Abásolo L, Prieto-García Á, Díaz-Valle D, et al.

    The British journal of ophthalmology 2016; (100(12)):1651-1655 doi:10.1136/bjophthalmol-2015-307774.

    PMID: 27030281

This page is for general education about intermediate uveitis and does not constitute medical advice. Do not start, stop, or rapidly taper corticosteroids or immunosuppressive medicines without guidance from your ophthalmologist or prescribing team.